$InflaRx(IFRX)$ Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpoint
得，第一条就是没啥显著的统计学意义。。。